Palella Jr FJ, Delaney KM, Moorman AC.
et al. for the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human
immunodeficiency virus infection. N Engl J Med.1998;338:853-860.
Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated
lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet.1999;353:2093-2099.
Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleukin 2 plus zidovudine in asymptomatic
individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr.1991;4:11-23.
Kovacs JA, Baseler M, Dewar RJ.
et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin
2 in patients with human immunodeficiency virus infection: a preliminary study. N Engl J Med.1995;332:567-575.
McMahon DK, Armstrong JA, Huang X-L.
et al. A phase I study of subcutaneous recombinant interleukin-2 in patients
with advanced HIV disease while on zidovudine. AIDS.1994;8:59-66.
Kovacs JA, Vogel S, Albert JM.
et al. Sustained increases in CD4 counts with intermittent interleukin 2 therapy
in HIV-infected patients with greater than 200 CD4 cells/mm3: results
of a randomized, controlled trial. N Engl J Med.1996;335:1350-1356.
Davey Jr RT, Chaitt DG, Piscitelli SC.
et al. Subcutaneous administration of interleukin-2 in HIV-1-infected persons. J Infect Dis.1997;175:781-789.
De Paoli P, Zanussi S, Simonelli C.
et al. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in
vitro cytokine production in HIV+ subjects. J Clin Invest.1997;100:2737-2743.
Emery S, Capra W, Vig P.
et al. IL-2 therapy for HIV disease: a meta-analysis of three randomized,
controlled trials. From: Fifth Conference on Retroviruses and Opportunistic Infections;
February 1-5, 1998; Chicago, Ill. Abstract 608.
Carr A, Emery S, Lloyd A.
et al. for the Australian IL-2 Study Group. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene
glycol-modified interleukin-2 in human immunodeficiency virus-infected patients:
a randomized, controlled, multicenter study. J Infect Dis.1998;178:992-999.
Davey Jr RT, Chaitt DG, Albert JM.
et al. A randomized trial of high- versus low-dose subcutaneous interleukin-2
outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis.1999;179:849-858.
1993 Revised classification system for HIV infection and expanded surveillance
case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep.1992;41(RR-17):4-19.
Revised guidelines for the performance of CD4+ T-cell determinations
in persons with human immunodeficiency virus (HIV) infections. MMWR Morb Mortal Wkly Rep.1994;42(RR-3):1-21.
Urdea MS, Wilber JC, Yeghiazarian T.
et al. Direct and quantitative detection of HIV-1 RNA in human plasma with
a branched DNA signal amplification assay. AIDS.1993;7(suppl 2):S11-S14.
Dewar R, Highbarger HC, Sarmiento MD.
et al. Application of branched DNA signal amplification to monitor human immunodeficiency
virus type 1 burden in human plasma. J Infect Dis.1994;170:1172-1179.
Pavur R, Nath R. Parametric versus rank transform procedures in the two-way factorial
experiment: a comparative study. J Stat Computation Simulation.1986;23:231-240.
Van Lunzen J, Tenner-Racs K, Racz P, Hufert FT, Lauer J, Stellbrink HJ. Effect of HAART +/− IL-2 on viral kinetics and T-cell reconstitution
in lymphoid tissues of asymptomatic HIV-1 infected patients. Int Conf AIDS.1998;12:787-788.
Hengge UR, Goos M, Esser S.
et al. Randomized, controlled phase II trial of subcutaneous interleukin-2
in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS.1998;12:F225-F234.
Levy Y, Capitant C, Houhou S.
et al. for the ANRS 048 Study Group. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic
HIV-1 infection: a randomised controlled trial. Lancet.1999;353:1923-1929.
Zanussi S, Simonelli C, Bortolin MT.
et al. Immunological changes in peripheral blood and in lymphoid tissue after
treatment of HIV-infected subjects with highly active anti-retroviral therapy
(HAART) or HAART + IL-2. Clin Exp Immunol.1999;116:486-492.
Arno A, Ruiz L, Juan M.
et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human
immunodeficiency virus type 1 in persons with ≤250/µL CD4 T cells
and undetectable plasma virus load. J Infect Dis.1999;180:56-60.
Jacobson EL, Pilaro F, Smith KA. Rational interleukin 2 therapy for HIV-positive individuals: daily
low doses enhance immune function without toxicity. Proc Natl Acad Sci U S A.1996;93:10405-10410.
Clark AG, Holodmiy M, Schwartz DH, Katzenstein DA, Merigan TC. Decrease in HIV provirus in peripheral blood mononuclear cells during
zidovudine and human rIL-2 administration. J Acquir Immune Defic Syndr.1992;5:52-59.
Simonelli C, Zanussi S, Sandri S.
et al. Concomitant therapy with subcutaneous interleukin-2 and zidovudine
plus didanosine in patients with early stage HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol.1999;20:20-27.
Izopet J, Salama G, Pasquier C.
et al. Ultra sensitive detection of plasma HIV-1 RNA for predicting the durability
of 3-drug antiretroviral therapy. In: Program and abstracts of the 5th Conference on Retroviruses and
Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 326.
Kempf DJ, Rode RA, Xu Y.
et al. The duration of viral suppression during protease inhibitor therapy
for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS.1998;12:F9-F14.